{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,25]],"date-time":"2026-06-25T11:17:19Z","timestamp":1782386239755,"version":"3.54.5"},"reference-count":132,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T00:00:00Z","timestamp":1780617600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Endocrinol."],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a highly prevalent condition that progresses from hepatic steatosis to steatohepatitis, fibrosis, and cirrhosis. While metabolic and inflammatory drivers of disease progression are well recognized, emerging evidence suggests that endocrine modulators, including the insulin-like growth factor binding proteins (IGFBPs), play important roles in MASLD. Beyond their canonical role as insulin-like growth factor (IGF) carriers, IGFBPs act as dynamic regulators of hepatic metabolism, inflammation, and fibrotic remodeling through both IGF-dependent and IGF-independent mechanisms. Growing evidence indicates that IGFBP1 and IGFBP2 confer metabolic protection by promoting lipid oxidation and increasing insulin sensitivity. IGFBP3 and IGFBP5 exhibit dual actions: they restrain lipogenesis at early stages but promote hepatocellular injury and stellate cell activation during fibrosis. IGFBP7 is a predominantly pathogenic modulator that impairs insulin signaling, drives ferroptosis, and fosters fibrosis. By contrast, IGFBP4 and IGFBP6 remain less well characterized. This review integrates recent mechanistic and translational findings on IGFBPs in MASLD with evidence accumulated from recent studies, highlighting their potential as biomarkers for disease staging and as therapeutic targets for interventions.<\/jats:p>","DOI":"10.3389\/fendo.2026.1853302","type":"journal-article","created":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:40:55Z","timestamp":1780638055000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Insulin-like growth factor binding proteins in metabolic dysfunction-associated steatotic liver disease"],"prefix":"10.3389","volume":"17","author":[{"given":"Kuo","family":"Fang","sequence":"first","affiliation":[{"name":"School of Medicine, The Chinese University of Hong Kong","place":["Shenzhen, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Miao","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Boston Children\u2019s Hospital","place":["Boston, MA, United States"]},{"name":"Department of Medicine, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guobin","family":"Song","sequence":"additional","affiliation":[{"name":"Division of Endocrinology, Boston Children\u2019s Hospital","place":["Boston, MA, United States"]},{"name":"Department of Medicine, Harvard Medical School","place":["Boston, MA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,6,5]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.1002\/edm2.70132","article-title":"Metabolic dysfunction-associated steatotic liver disease (Masld): Mechanisms, clinical implications and therapeutic advances","volume":"8","author":"Miller","year":"2025","journal-title":"Endocrinol Diabetes Metab"},{"key":"B2","doi-asserted-by":"publisher","first-page":"2761","DOI":"10.3390\/biomedicines11102761","article-title":"Pathology and pathogenesis of metabolic dysfunction-associated steatotic liver disease-associated hepatic tumors","volume":"11","author":"Takahashi","year":"2023","journal-title":"Biomedicines"},{"key":"B3","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3390\/metabo14010012","article-title":"Lipid metabolism in metabolic-associated steatotic liver disease (Masld)","volume":"14","author":"Syed-Abdul","year":"2023","journal-title":"Metabolites"},{"key":"B4","doi-asserted-by":"publisher","DOI":"10.1080\/14656566.2024.2426680","article-title":"Metabolic-associated steatotic liver disease and hepatocellular carcinoma","volume":"25","author":"Catalano","year":"2024","journal-title":"Expert Opin Pharmacother"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1016\/j.diabres.2024.111652","article-title":"Type 2 diabetes mellitus and cardiometabolic outcomes in metabolic dysfunction-associated steatotic liver disease population","volume":"211","author":"Chew","year":"2024","journal-title":"Diabetes Res Clin Pract"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2024.0431","article-title":"Epidemiology of metabolic dysfunction-associated steatotic liver disease","volume":"31","author":"Younossi","year":"2025","journal-title":"Clin Mol Hepatol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.14218\/jcth.2024.00019","article-title":"Mechanism of metabolic dysfunction-associated steatotic liver disease: Important role of lipid metabolism","volume":"12","author":"Feng","year":"2024","journal-title":"J Clin Transl Hepatol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1155\/ijh\/5580454","article-title":"Metabolic-associated steatotic liver disease: From molecular mechanisms to novel therapies","volume":"2025","author":"Cooper","year":"2025","journal-title":"Int J Hepatol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2015.06.003","article-title":"Insulin-like growth factor binding-protein-3 (Igfbp-3)","volume":"29","author":"Ranke","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1016\/j.beem.2015.06.002","article-title":"Insulin-like growth factor binding proteins 4-6","volume":"29","author":"Bach","year":"2015","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2012.00038","article-title":"Insulin-like growth factor binding proteins: A structural perspective","volume":"3","author":"Forbes","year":"2012","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B12","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1111\/j.1651-2227.1999.tb14349.x","article-title":"Insulin-like growth factor binding proteins: A proposed superfamily","volume":"88","author":"Hwa","year":"1999","journal-title":"Acta Paediatr Suppl"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1210\/edrv.20.6.0382","article-title":"The insulin-like growth factor-binding protein (Igfbp) superfamily","volume":"20","author":"Hwa","year":"1999","journal-title":"Endocr Rev"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00117","article-title":"Igf-binding proteins: Why do they exist and why are there so many","volume":"9","author":"Allard","year":"2018","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1007\/s12031-015-0589-3","article-title":"Insulin-like growth factor binding protein-2 promotes adhesion of endothelial progenitor cells to endothelial cells via integrin A5\u03b21","volume":"57","author":"Feng","year":"2015","journal-title":"J Mol Neurosci"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1677\/jme.0.0320859","article-title":"Integrin-mediated action of insulin-like growth factor binding protein-2 in tumor cells","volume":"32","author":"Sch\u00fctt","year":"2004","journal-title":"J Mol Endocrinol"},{"key":"B17","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1677\/jme.1.01955","article-title":"Igf-independent effects of Igfbp-2 on the human breast cancer cell line Hs578t","volume":"37","author":"Frommer","year":"2006","journal-title":"J Mol Endocrinol"},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.273.29.18347","article-title":"Insulin-like growth factor-binding protein (Igfbp)-3 and Igfbp-5 share a common nuclear transport pathway in T47d human breast carcinoma cells","volume":"273","author":"Schedlich","year":"1998","journal-title":"J Biol Chem"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.M002208200","article-title":"Nuclear import of insulin-like growth factor-binding protein-3 and -5 is mediated by the importin beta subunit","volume":"275","author":"Schedlich","year":"2000","journal-title":"J Biol Chem"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1507\/endocrj.EJ17-0156","article-title":"Importin \u03b1-importin \u03b2 complex mediated nuclear translocation of insulin-like growth factor binding protein-5","volume":"64","author":"Sun","year":"2017","journal-title":"Endocr J"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1677\/jme.0.0260229","article-title":"The carboxy-terminal domain of Igf-binding protein-5 inhibits heparin binding to a site in the central domain","volume":"26","author":"Song","year":"2001","journal-title":"J Mol Endocrinol"},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1210\/endo.137.11.8895319","article-title":"Binding of insulin-like growth factor (Igf) I or II to Igf-binding protein-2 enables it to bind to heparin and extracellular matrix","volume":"137","author":"Arai","year":"1996","journal-title":"Endocrinology"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1210\/en.2002-220798","article-title":"Phosphorylation of insulin-like growth factor binding protein-3 by deoxyribonucleic acid-dependent protein kinase reduces ligand binding and enhances nuclear accumulation","volume":"144","author":"Schedlich","year":"2003","journal-title":"Endocrinology"},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1016\/j.domaniend.2005.02.021","article-title":"Insulin-like growth factor binding proteins initiate cell death and extracellular matrix remodeling in the mammary gland","volume":"29","author":"Flint","year":"2005","journal-title":"Domest Anim Endocrinol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.943300","article-title":"Igfbps were associated with stemness, inflammation, extracellular matrix remodeling and poor prognosis of low-grade glioma","volume":"13","author":"Liu","year":"2022","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B26","doi-asserted-by":"publisher","DOI":"10.2337\/db16-0997","article-title":"Insulin-like growth factor binding protein 1 could improve glucose regulation and insulin sensitivity through its Rgd domain","volume":"66","author":"Haywood","year":"2017","journal-title":"Diabetes"},{"key":"B27","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2825(1999)13:4<166::AID-JCLA5>3.0.CO;2-X","article-title":"Insulin-like growth factors (igf-i, free igf-i and igf-ii) and insulin-like growth factor binding proteins (igfbp-2, igfbp-3, igfbp-6, and als) in blood circulation","volume":"13","author":"Yu","year":"1999","journal-title":"J Clin Lab Anal"},{"key":"B28","article-title":"Structure-function relationships in the heparin-binding C-terminal region of insulin-like growth factor binding protein-3","volume":"6","author":"Booth","year":"1996","journal-title":"Growth Regul"},{"key":"B29","doi-asserted-by":"publisher","first-page":"429","DOI":"10.3390\/medicina60030429","article-title":"Insulin-like growth factor binding proteins and cellular senescence are involved in the progression of non-alcoholic fatty liver disease and fibrosis in a mouse model","volume":"60","author":"Guzman","year":"2024","journal-title":"Med (Kaunas)"},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1006\/geno.1998.5283","article-title":"Structure and transcription regulation of the human insulin-like growth factor binding protein 4 gene (igfbp4)","volume":"49","author":"Zazzi","year":"1998","journal-title":"Genomics"},{"key":"B31","doi-asserted-by":"publisher","DOI":"10.1016\/j.ghir.2006.11.003","article-title":"Pregnancy-associated plasma protein-a (papp-a): a local regulator of igf bioavailability through cleavage of igfbps","volume":"17","author":"Boldt","year":"2007","journal-title":"Growth Hormone IGF Res"},{"key":"B32","doi-asserted-by":"publisher","DOI":"10.1007\/s003359901005","article-title":"Characterization and chromosomal localization of the human insulin-like growth factor-binding protein 6 gene","volume":"10","author":"Ehrenborg","year":"1999","journal-title":"Mamm Genome"},{"key":"B33","doi-asserted-by":"publisher","DOI":"10.1210\/jc.2008-1245","article-title":"Insulin-like growth factor binding protein 1 as a novel specific marker of hepatic insulin sensitivity","volume":"93","author":"Kotronen","year":"2008","journal-title":"J Clin Endocrinol Metab"},{"key":"B34","doi-asserted-by":"publisher","first-page":"6400","DOI":"10.3390\/ijms25126400","article-title":"Igf-1 and Igfbp-1 as possible predictors of response to lifestyle intervention-results from randomized controlled trials","volume":"25","author":"Meyer","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B35","doi-asserted-by":"publisher","DOI":"10.1111\/jgh.15627","article-title":"Insulin-like growth factor binding protein 1 ameliorates lipid accumulation and inflammation in nonalcoholic fatty liver disease","volume":"36","author":"Pan","year":"2021","journal-title":"J Gastroenterol Hepatol"},{"key":"B36","doi-asserted-by":"publisher","DOI":"10.3109\/17477166.2010.544739","article-title":"Longitudinal association between Igfbp-1 levels and parameters of the metabolic syndrome in obese children before and after weight loss","volume":"6","author":"Reinehr","year":"2011","journal-title":"Int J Pediatr Obes"},{"key":"B37","doi-asserted-by":"publisher","DOI":"10.1080\/00365521.2017.1379556","article-title":"Igfbp-1 and Igf-I as markers for advanced fibrosis in Nafld - a pilot study","volume":"52","author":"Hagstr\u00f6m","year":"2017","journal-title":"Scand J Gastroenterol"},{"key":"B38","doi-asserted-by":"publisher","DOI":"10.1016\/j.cbi.2024.111162","article-title":"Salvianolic acid a attenuates non-alcoholic fatty liver disease by regulating the Ampk-Igfbp1 pathway","volume":"400","author":"Zhu","year":"2024","journal-title":"Chem Biol Interact"},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.1530\/joe-22-0073","article-title":"Serpina3n deficiency attenuates steatosis and enhances insulin signaling in male mice","volume":"256","author":"Tran","year":"2023","journal-title":"J Endocrinol"},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.77146","article-title":"Insulin-like growth factor-1 (Igf-1) deficiency and metabolic-dysfunction-associated steatotic liver disease in a young patient","volume":"17","author":"Flourou","year":"2025","journal-title":"Cureus"},{"key":"B41","doi-asserted-by":"publisher","DOI":"10.1172\/jci118982","article-title":"Impaired glucose homeostasis in insulin-like growth factor binding protein-1 transgenic mice","volume":"98","author":"Rajkumar","year":"1996","journal-title":"J Clin Invest"},{"key":"B42","doi-asserted-by":"publisher","DOI":"10.1177\/0004563213495818","article-title":"Delta insulin-like growth factor binding protein-1 (\u0394igfbp-1): a marker of hepatic insulin resistance","volume":"51","author":"Borai","year":"2014","journal-title":"Ann Clin Biochem"},{"key":"B43","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2024.102026","article-title":"Igfbp2 functions as an endogenous protector against hepatic steatosis via suppression of the Egfr-Stat3 pathway","volume":"89","author":"Zhai","year":"2024","journal-title":"Mol Metab"},{"key":"B44","doi-asserted-by":"publisher","first-page":"4144","DOI":"10.3390\/ijms21114144","article-title":"Physiological disturbance in fatty liver energy metabolism converges on Igfbp2 abundance and regulation in mice and men","volume":"21","author":"Fahlbusch","year":"2020","journal-title":"Int J Mol Sci"},{"key":"B45","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520935219","article-title":"Circulating Igfbp-2 levels are inversely associated with the incidence of nonalcoholic fatty liver disease: a cohort study","volume":"48","author":"Yang","year":"2020","journal-title":"J Int Med Res"},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1093\/hmg\/ddw121","article-title":"Early hypermethylation of hepatic Igfbp2 results in its reduced expression preceding fatty liver in mice","volume":"25","author":"Kammel","year":"2016","journal-title":"Hum Mol Genet"},{"key":"B47","doi-asserted-by":"publisher","DOI":"10.1111\/dom.15925","article-title":"Causal relationship between key genes and metabolic dysfunction-associated fatty liver disease risk mediated by immune cells: a Mendelian randomization and mediation analysis","volume":"26","author":"Feng","year":"2024","journal-title":"Diabetes Obes Metab"},{"key":"B48","doi-asserted-by":"publisher","DOI":"10.1096\/fj.202201950R","article-title":"Fgf1 ameliorates obesity-associated hepatic steatosis by reversing Igfbp2 hypermethylation","volume":"37","author":"Wang","year":"2023","journal-title":"FASEB J"},{"key":"B49","doi-asserted-by":"publisher","DOI":"10.2147\/DMSO.S466051","article-title":"Combination of waist circumference and circulating levels of Igfbp-2 as a simple screening tool for early detection of metabolic dysfunction-associated steatotic liver disease","volume":"17","author":"Rauzier","year":"2024","journal-title":"Diabetes Metab Syndr Obes"},{"key":"B50","doi-asserted-by":"publisher","DOI":"10.1006\/prep.1999.1075","article-title":"Adenoviral-mediated expression of human insulin-like growth factor-binding protein-3","volume":"16","author":"Firth","year":"1999","journal-title":"Protein Expr Purif"},{"key":"B51","doi-asserted-by":"publisher","DOI":"10.1096\/fj.201600427R","article-title":"Suppression of Igf binding protein-3 by palmitate promotes hepatic inflammatory responses","volume":"30","author":"Min","year":"2016","journal-title":"FASEB J"},{"key":"B52","doi-asserted-by":"publisher","first-page":"196","DOI":"10.3760\/cma.j.issn.1007-3418.2012.03.012","article-title":"Expression and significance of insulin-like growth factor-1 and insulin-like growth factor binding protein-3 in hepatocyte steatosis model","volume":"20","author":"Zhang","year":"2012","journal-title":"Zhonghua Gan Zang Bing Za Zhi"},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1007\/s12072-007-9007-4","article-title":"Role of growth hormone, insulin-like growth factor 1 and insulin-like growth factor-binding protein 3 in development of non-alcoholic fatty liver disease","volume":"1","author":"Ichikawa","year":"2007","journal-title":"Hepatol Int"},{"key":"B54","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2014.01.052","article-title":"Insulin-like growth factor-I and -II levels are associated with the progression of nonalcoholic fatty liver disease in obese children","volume":"165","author":"Cianfarani","year":"2014","journal-title":"J Pediatr"},{"key":"B55","article-title":"Insulin-like growth factor binding protein 3 promoter variant (Rs2854744) is associated with nonalcoholic fatty liver disease","volume":"68","author":"Mahmoudi","year":"2023","journal-title":"Arch Endocrinol Metab"},{"key":"B56","doi-asserted-by":"publisher","DOI":"10.1210\/en.2010-0672","article-title":"Evidence of a role for insulin-like growth factor binding protein (Igfbp)-3 in metabolic regulation","volume":"151","author":"Yamada","year":"2010","journal-title":"Endocrinology"},{"key":"B57","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2020.05.005","article-title":"Gipc-regulated Igfbp-3 promotes Hsc migration in vitro and portal hypertension in vivo through a B1-integrin pathway","volume":"10","author":"Yaqoob","year":"2020","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B58","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2020.117997","article-title":"Igfbp5 modulates lipid metabolism and insulin sensitivity through activating Ampk pathway in non-alcoholic fatty liver disease","volume":"256","author":"Xiao","year":"2020","journal-title":"Life Sci"},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2021.103233","article-title":"Single-cell rna transcriptome landscape of hepatocytes and non-parenchymal cells in healthy and nafld mouse liver","volume":"24","author":"Su","year":"2021","journal-title":"iScience"},{"key":"B60","doi-asserted-by":"publisher","DOI":"10.1186\/1755-1536-3-3","article-title":"Insulin-like growth factor binding protein 5 enhances survival of lx2 human hepatic stellate cells","volume":"3","author":"Sokolovic","year":"2010","journal-title":"Fibrogenesis Tissue Repair"},{"key":"B61","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1038\/s41419-023-06351-5","article-title":"The chromatin remodeling protein brg1 regulates hsc-myofibroblast differentiation and liver fibrosis","volume":"14","author":"Zhu","year":"2023","journal-title":"Cell Death Dis"},{"key":"B62","doi-asserted-by":"publisher","first-page":"996","DOI":"10.1016\/j.bbadis.2012.02.022","article-title":"Overexpression of insulin like growth factor binding protein 5 reduces liver fibrosis in chronic cholangiopathy","volume":"1822","author":"Sokolovic","year":"2012","journal-title":"Biochim Biophys Acta"},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.1097\/MEG.0b013e32834e8041","article-title":"Serum concentrations of human insulin-like growth factor-1 and levels of insulin-like growth factor-binding protein-5 in patients with nonalcoholic fatty liver disease: association with liver histology","volume":"24","author":"Colak","year":"2012","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.1210\/clinem\/dgaa792","article-title":"Relationship of Igf-1 and Igf-binding proteins to disease severity and glycemia in nonalcoholic fatty liver disease","volume":"106","author":"Stanley","year":"2021","journal-title":"J Clin Endocrinol Metab"},{"key":"B65","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.49.30729","article-title":"Inhibition of insulin receptor activation by insulin-like growth factor binding proteins","volume":"272","author":"Yamanaka","year":"1997","journal-title":"J Biol Chem"},{"key":"B66","doi-asserted-by":"publisher","DOI":"10.1126\/scisignal.2003184","article-title":"Igfbp7 binds to the igf-1 receptor and blocks its activation by insulin-like growth factors","volume":"5","author":"Evdokimova","year":"2012","journal-title":"Sci Signal"},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1421438","article-title":"Insulin-like growth factor-binding protein 7 (igfbp7): a microenvironment-dependent regulator of angiogenesis and vascular remodeling","volume":"12","author":"Lit","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1420862","article-title":"The multifaceted role of insulin-like growth factor binding protein 7","volume":"12","author":"Chen","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B69","doi-asserted-by":"publisher","first-page":"4564","DOI":"10.1038\/s41467-024-48956-0","article-title":"Development of a novel non-invasive biomarker panel for hepatic fibrosis in masld","volume":"15","author":"Verschuren","year":"2024","journal-title":"Nat Commun"},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2023.122086","article-title":"Depletion of igfbp7 alleviates zebrafish nafld progression through inhibiting hepatic ferroptosis","volume":"332","author":"Wang","year":"2023","journal-title":"Life Sci"},{"key":"B71","doi-asserted-by":"publisher","DOI":"10.1111\/1440-1681.13159","article-title":"Insulin-like growth factor binding protein 7 accelerates hepatic steatosis and insulin resistance in non-alcoholic fatty liver disease","volume":"46","author":"Yan","year":"2019","journal-title":"Clin Exp Pharmacol Physiol"},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.15.3246","article-title":"Insulin-like growth factor binding protein-7 induces activation and transdifferentiation of hepatic stellate cells in vitro","volume":"15","author":"Liu","year":"2009","journal-title":"World J Gastroenterol"},{"key":"B73","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i21.6523","article-title":"Igfbprp1 induces liver fibrosis by inducing hepatic stellate cell activation and hepatocyte apoptosis via smad2\/3 signaling","volume":"20","author":"Yun Zhang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2017.00554","article-title":"Insulin-like growth factor binding protein 6 in rheumatoid arthritis: a possible novel chemotactic factor","volume":"8","author":"Alunno","year":"2017","journal-title":"Front Immunol"},{"key":"B75","doi-asserted-by":"publisher","first-page":"1127","DOI":"10.1038\/s42003-025-08527-5","article-title":"Pantothenic acid ameliorates hepatic fibrosis by targeting igfbp6 to regulate the tgf-\u03b2\/smads pathway","volume":"8","author":"Jin","year":"2025","journal-title":"Commun Biol"},{"key":"B76","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1053\/j.gastro.2019.11.312","article-title":"Mafld: A consensus-driven proposed nomenclature for metabolic associated fatty liver disease","volume":"158","author":"Eslam","year":"2020","journal-title":"Gastroenterology"},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.1016\/j.aohep.2025.101898","article-title":"Global burden and future trends of metabolic dysfunction-associated steatotic liver disease: 1990\u20132021 to 2045","volume":"30","author":"Kan","year":"2025","journal-title":"Ann Hepatol"},{"key":"B78","doi-asserted-by":"publisher","DOI":"10.1007\/s10198-020-01256-y","article-title":"Disease burden and economic impact of diagnosed non-alcoholic steatohepatitis (Nash) in the United Kingdom (Uk) in 2018","volume":"22","author":"Morgan","year":"2021","journal-title":"Eur J Health Econ"},{"key":"B79","doi-asserted-by":"publisher","DOI":"10.3138\/canlivj-2025-0053","article-title":"Clinical and biochemical features of diagnosed and undiagnosed patients with metabolic dysfunction-associated steatotic liver disease","volume":"8","author":"Minuk","year":"2025","journal-title":"Can Liver J"},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.3350\/cmh.2022.0398","article-title":"Risk factors in nonalcoholic fatty liver disease","volume":"29","author":"Ko","year":"2023","journal-title":"Clin Mol Hepatol"},{"key":"B81","doi-asserted-by":"publisher","DOI":"10.1097\/hep.0000000000000913","article-title":"Epidemiology, screening, and co-management of type 2 diabetes mellitus and metabolic dysfunction-associated steatotic liver disease","volume":"83","author":"Qi","year":"2024","journal-title":"Hepatology"},{"key":"B82","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2024.1425145","article-title":"Identifying metabolic dysfunction-associated steatotic liver disease in patients with type 2 diabetes mellitus using clinic-based prediction tools","volume":"11","author":"Alkaabi","year":"2024","journal-title":"Front Med (Lausanne)"},{"key":"B83","doi-asserted-by":"publisher","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic dysfunction-associated steatotic liver disease (Masld): A state-of-the-art review","volume":"32","author":"Chan","year":"2023","journal-title":"J Obes Metab Syndr"},{"key":"B84","doi-asserted-by":"crossref","DOI":"10.36255\/exonpublications.livercancer.2021.ch3","article-title":"Non-alcoholic fatty liver disease progression to non-alcoholic steatohepatitis-related primary liver cancer","volume-title":"Liver cancer","author":"Udoh","year":"2021"},{"key":"B85","doi-asserted-by":"publisher","first-page":"88","DOI":"10.2152\/jmi.56.88","article-title":"Saturated fatty acids and insulin resistance","volume":"56","author":"Funaki","year":"2009","journal-title":"J Med Invest"},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.1089\/jmf.2022.K.0028","article-title":"Saturated fatty acid-induced impairment of hepatic lipid metabolism is worsened by prohibitin 1 deficiency in hepatocytes","volume":"25","author":"Yanran","year":"2022","journal-title":"J Med Food"},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.107401","article-title":"The unfolded protein response and hepatic lipid metabolism in non alcoholic fatty liver disease","volume":"203","author":"Song","year":"2019","journal-title":"Pharmacol Ther"},{"key":"B88","doi-asserted-by":"publisher","DOI":"10.1111\/hepr.12658","article-title":"Lipotoxicity pathways intersect in hepatocytes: Endoplasmic reticulum stress, c-Jun N-terminal kinase-1, and death receptors","volume":"46","author":"Akazawa","year":"2016","journal-title":"Hepatol Res"},{"key":"B89","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1186\/s12944-024-02108-x","article-title":"Updated mechanisms of Masld pathogenesis","volume":"23","author":"Li","year":"2024","journal-title":"Lipids Health Dis"},{"key":"B90","doi-asserted-by":"publisher","DOI":"10.1016\/j.jcmgh.2023.02.010","article-title":"Hepatic stellate cells: Dictating outcome in nonalcoholic fatty liver disease","volume":"15","author":"Wiering","year":"2023","journal-title":"Cell Mol Gastroenterol Hepatol"},{"key":"B91","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2019.11.311","article-title":"Mechanisms of fibrosis development in nonalcoholic steatohepatitis","volume":"158","author":"Schwabe","year":"2020","journal-title":"Gastroenterology"},{"key":"B92","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","article-title":"Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: A systematic review and meta-analysis","volume":"21","author":"Ng","year":"2023","journal-title":"Clin Gastroenterol Hepatol"},{"key":"B93","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1186\/s12876-025-03912-0","article-title":"Clinical characteristics of Masld\/Metald\/Mafld\/Nafld and the relative risk analysis on metabolic disorders","volume":"25","author":"Peng","year":"2025","journal-title":"BMC Gastroenterol"},{"key":"B94","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.sleep.2022.04.006","article-title":"Obstructive sleep apnea, intermittent hypoxia and non-alcoholic fatty liver disease","volume":"95","author":"Ji","year":"2022","journal-title":"Sleep Med"},{"key":"B95","doi-asserted-by":"publisher","DOI":"10.1172\/jci186423","article-title":"Metabolic dysfunction-associated steatotic liver disease and the gut microbiome: Pathogenic insights and therapeutic innovations","volume":"135","author":"Schnabl","year":"2025","journal-title":"J Clin Invest"},{"key":"B96","doi-asserted-by":"publisher","DOI":"10.5493\/wjem.v15.i4.107316","article-title":"Gut microbiota and metabolic-associated steatosis liver disease: Unveiling mechanisms and opportunities for therapeutic intervention","volume":"15","author":"Rusman","year":"2025","journal-title":"World J Exp Med"},{"key":"B97","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2024.1433857","article-title":"Systemic impacts of metabolic dysfunction-associated steatotic liver disease (Masld) and metabolic dysfunction-associated steatohepatitis (Mash) on heart, muscle, and kidney related diseases","volume":"12","author":"Sandireddy","year":"2024","journal-title":"Front Cell Dev Biol"},{"key":"B98","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2007.06.079","article-title":"Regulation of insulin-like growth factor binding protein-1 expression during aging","volume":"361","author":"Rutkute","year":"2007","journal-title":"Biochem Biophys Res Commun"},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.79.6.7527416","article-title":"Differential cellular synthesis of insulin-like growth factor binding protein-1 (Igfbp-1) and Igfbp-3 within human liver","volume":"79","author":"Arany","year":"1994","journal-title":"J Clin Endocrinol Metab"},{"key":"B100","doi-asserted-by":"publisher","DOI":"10.1016\/j.tem.2009.01.002","article-title":"Igf-dependent and Igf-independent actions of Igf-binding protein-1 and -2: Implications for metabolic homeostasis","volume":"20","author":"Wheatcroft","year":"2009","journal-title":"Trends Endocrinol Metab"},{"key":"B101","doi-asserted-by":"publisher","DOI":"10.1016\/0955-2235(96)00006-3","article-title":"Regulation of igfbp-1 in humans","volume":"6","author":"Brismar","year":"1995","journal-title":"Prog Growth Factor Res"},{"key":"B102","doi-asserted-by":"publisher","DOI":"10.1530\/eje-22-0034","article-title":"Low Igf1 and high Igfbp1 predict diabetes onset in prediabetic patients","volume":"187","author":"Meyer","year":"2022","journal-title":"Eur J Endocrinol"},{"key":"B103","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.3390\/ijms25063481","article-title":"Anaerobutyricum soehngenii reduces hepatic lipogenic pathways and increases intestinal gluconeogenic gene expression in metabolic-dysfunction-associated steatotic liver disease (Masld) mice","volume":"25","author":"Mak","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B104","doi-asserted-by":"publisher","DOI":"10.1016\/j.rgmxen.2019.08.002","article-title":"Production of insulin-like growth factor-binding proteins during the development of hepatic fibrosis due to chronic hepatitis C","volume":"85","author":"Rosique-Oramas","year":"2020","journal-title":"Rev Gastroenterolog\u00eda M\u00e9xico (English Edition)"},{"key":"B105","doi-asserted-by":"publisher","DOI":"10.24875\/ric.19002995","article-title":"Insulin-like growth factor binding protein-1, non-alcoholic fatty liver disease, and its relationship with fructose consumption in children with obesity","volume":"71","author":"Flores-Ram\u00edrez","year":"2019","journal-title":"Rev Invest Clin"},{"key":"B106","doi-asserted-by":"publisher","DOI":"10.1210\/jcem.83.6.4857","article-title":"Insulin-like growth factor binding protein-I levels are strongly associated with insulin sensitivity and obesity in early pubertal children","volume":"83","author":"Travers","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"B107","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.840361","article-title":"Fasting serum Igfbp-1 as a marker of insulin resistance in diverse school age groups","volume":"13","author":"Bhangoo","year":"2022","journal-title":"Front Endocrinol"},{"key":"B108","doi-asserted-by":"publisher","DOI":"10.1038\/srep24740","article-title":"Phosphorylated Igfbp-1 as a non-invasive predictor of liver fat in Nafld","volume":"6","author":"Pet\u00e4j\u00e4","year":"2016","journal-title":"Sci Rep"},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22031133","article-title":"Potential role of insulin growth-factor-binding protein 2 as therapeutic target for obesity-related insulin resistance","volume":"22","author":"Boughanem","year":"2021","journal-title":"Int J Mol Sci"},{"key":"B110","doi-asserted-by":"publisher","DOI":"10.3803\/EnM.2017.32.1.11","article-title":"Recent insights into insulin-like growth factor binding protein 2 transcriptional regulation","volume":"32","author":"Shin","year":"2017","journal-title":"Endocrinol Metab (Seoul)"},{"key":"B111","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2023.1222101","article-title":"Plasma Igfbp-2 levels reveal heterogeneity in hepatic fat content in adults with excess visceral adiposity","volume":"14","author":"Rauzier","year":"2023","journal-title":"Front Endocrinol (Lausanne)"},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1152\/ajpendo.00528.2019","article-title":"Downregulated microrna-130b-5p prevents lipid accumulation and insulin resistance in a murine model of nonalcoholic fatty liver disease","volume":"319","author":"Liu","year":"2020","journal-title":"Am J Physiol Endocrinol Metab"},{"key":"B113","doi-asserted-by":"publisher","DOI":"10.7150\/ijbs.7.536","article-title":"Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target","volume":"7","author":"Wang","year":"2011","journal-title":"Int J Biol Sci"},{"key":"B114","doi-asserted-by":"publisher","DOI":"10.1080\/19490976.2023.2238959","article-title":"Protection against metabolic associated fatty liver disease by protocatechuic acid","volume":"15","author":"Tan","year":"2023","journal-title":"Gut Microbes"},{"key":"B115","doi-asserted-by":"publisher","DOI":"10.1016\/s0764-4469(97)85695-8","article-title":"Proteolytic fragments of insulin-like growth factor binding protein-3: N-terminal sequences and relationships between structure and biological activity","volume":"320","author":"Lalou","year":"1997","journal-title":"C R Acad Sci III"},{"key":"B116","doi-asserted-by":"publisher","DOI":"10.4103\/1735-5362.235160","article-title":"In silico interaction of insulin-like growth factor binding protein 3 with insulin-like growth factor 1","volume":"13","author":"Jafari","year":"2018","journal-title":"Res Pharm Sci"},{"key":"B117","doi-asserted-by":"publisher","DOI":"10.5483\/bmbrep.2002.35.2.186","article-title":"Interaction between acid-labile subunit and insulin-like growth factor binding protein 3 expressed in Xenopus oocytes","volume":"35","author":"Choi","year":"2002","journal-title":"J Biochem Mol Biol"},{"key":"B118","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnad008","article-title":"Signaling pathways of the insulin-like growth factor binding proteins","volume":"44","author":"Baxter","year":"2023","journal-title":"Endocr Rev"},{"key":"B119","doi-asserted-by":"publisher","DOI":"10.1016\/j.molmet.2021.101245","article-title":"Insulin-like growth factors: ligands, binding proteins, and receptors","volume":"52","author":"LeRoith","year":"2021","journal-title":"Mol Metab"},{"key":"B120","doi-asserted-by":"publisher","DOI":"10.1002\/mc.21900","article-title":"Functional polymorphisms in the insulin-like binding protein-3 gene may modulate susceptibility to differentiated thyroid carcinoma in Caucasian Americans","author":"Xu","year":"2012","journal-title":"Mol Carcinog"},{"key":"B121","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1080\/00365521.2025.2490996","article-title":"Proteomic signatures for fibrosis in masld: a biopsy-proven dual-cohort study","volume":"60","author":"Blomdahl","year":"2025","journal-title":"Scand J Gastroenterol"},{"key":"B122","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2025-335598","article-title":"Thrombospondin-2 is a performant biomarker of at-risk mash and advanced mash fibrosis in a large multicentre european cohort","volume":"75","author":"Ratziu","year":"2025","journal-title":"Gut"},{"key":"B123","doi-asserted-by":"publisher","DOI":"10.1111\/liv.70169","article-title":"Prognostic value of the tlm3 biomarker panel for early fibrosis development in masld within the general population","volume":"45","author":"van Son","year":"2025","journal-title":"Liver Int"},{"key":"B124","doi-asserted-by":"publisher","DOI":"10.1016\/j.isci.2024.110767","article-title":"Igfbp7 is upregulated in islets from t2d donors and reduces insulin secretion","volume":"27","author":"Westholm","year":"2024","journal-title":"iScience"},{"key":"B125","doi-asserted-by":"publisher","first-page":"101687","DOI":"10.1016\/j.jhepr.2025.101687","article-title":"Plasma igfbp7 improves risk reclassification for liver-related outcomes: insights from proteo-transcriptomic profiling","volume":"8","author":"Liang","year":"2026","journal-title":"JHEP Rep"},{"key":"B126","doi-asserted-by":"publisher","DOI":"10.1002\/jcb.24804","article-title":"Insulin-like growth factor binding protein 4 enhances cardiomyocytes induction in murine-induced pluripotent stem cells","volume":"115","author":"Xue","year":"2014","journal-title":"J Cell Biochem"},{"key":"B127","doi-asserted-by":"publisher","DOI":"10.1016\/j.biomaterials.2011.09.070","article-title":"Cardiac differentiation of embryonic stem cells by substrate immobilization of insulin-like growth factor binding protein 4 with elastin-like polypeptides","volume":"33","author":"Minato","year":"2012","journal-title":"Biomaterials"},{"key":"B128","doi-asserted-by":"publisher","DOI":"10.1016\/j.neulet.2017.01.066","article-title":"Recombinant insulin-like growth factor binding protein-4 inhibits proliferation and promotes differentiation of neural progenitor cells","volume":"642","author":"Niu","year":"2017","journal-title":"Neurosci Lett"},{"key":"B129","doi-asserted-by":"publisher","DOI":"10.1159\/000477873","article-title":"Age-related insulin-like growth factor binding protein-4 overexpression inhibits osteogenic differentiation of rat mesenchymal stem cells","volume":"42","author":"Wu","year":"2017","journal-title":"Cell Physiol Biochem"},{"key":"B130","doi-asserted-by":"publisher","DOI":"10.1155\/2021\/1219593","article-title":"The rise of igfbp4 in people with obstructive sleep apnea and multilevel sleep surgery recovers its basal levels","volume":"2021","author":"Alterki","year":"2021","journal-title":"Dis Markers"},{"key":"B131","doi-asserted-by":"publisher","DOI":"10.1210\/endo.142.1.7903","article-title":"Interleukin-6 stimulates hepatic insulin-like growth factor binding protein-4 messenger ribonucleic acid and protein","volume":"142","author":"Fern\u00e1ndez-Celem\u00edn","year":"2001","journal-title":"Endocrinology"},{"key":"B132","doi-asserted-by":"publisher","first-page":"4","DOI":"10.3892\/ijo.2024.5710","article-title":"Mybbp1a-mediated igfbp4 promoter methylation promotes epithelial-mesenchymal transition and metastasis through activation of notch pathway in liver cancer","volume":"66","author":"Sun","year":"2025","journal-title":"Int J Oncol"}],"container-title":["Frontiers in Endocrinology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1853302\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,5]],"date-time":"2026-06-05T05:40:58Z","timestamp":1780638058000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fendo.2026.1853302\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,5]]},"references-count":132,"alternative-id":["10.3389\/fendo.2026.1853302"],"URL":"https:\/\/doi.org\/10.3389\/fendo.2026.1853302","relation":{},"ISSN":["1664-2392"],"issn-type":[{"value":"1664-2392","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6,5]]},"article-number":"1853302"}}